As of June 30 the Company had $149.2M in cash, liquidity funds, time deposits, and U.S treasury bills. “This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial – an important milestone in our development efforts for people living with geographic atrophy,” said Dr. Tom Lin, Chairman and CEO of Belite Bio (BLTE). “We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio, Inc. ADR (BLTE) Q2 Earnings Cheat Sheet
- Belite Bio Announces $15 Million Direct Offering
- Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering
- Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
- Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations